Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atrophy of Vagina Clear all
Completed Phase 2 Interventional

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

NCT02670785
View directory record Official record
Conditions
Vulvovaginal Atrophy, Menopause, Dyspareunia
Interventions
Estradiol Vaginal Capsule (EVC), Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Tucson, Arizona • San Diego, California • New London, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 3 Interventional

Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis

NCT00137371
View directory record Official record
Conditions
Atrophic Vaginitis, Atrophy, Vaginitis
Interventions
PVC (daily for 21 days, 7 days off), PVC (twice weekly)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
480 participants
Timeline
2005 – 2007
U.S. locations
32
States / cities
Tucson, Arizona • Encinitas, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2007 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Evaluate Long-Term Safety and Efficacy WC3011 (Estradiol Vaginal Cream)

NCT01455597
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
64
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 28, 2026, 1:04 PM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Early Phase 1 Interventional

Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness

NCT02029053
View directory record Official record
Conditions
Menopausal and Perimenopausal Disorder, Unspecified, Atrophic Vaginitis
Interventions
Vaginal Lubrication Ring for Vaginal Dryness
Device
Lead sponsor
J3 Bioscience, Inc.
Industry
Eligibility
35 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

NCT00361569
View directory record Official record
Conditions
Menopause
Interventions
DR-2041a, DR-2041b, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
97
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2015 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

NCT03294538
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function

NCT03493126
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Estradiol, Placebo
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Sep 28, 2026, 1:04 PM EDT
Recruiting Not applicable Interventional

VALOR: Vaginal Atrophy & Long-term Observation of Recovery

NCT05953090
View directory record Official record
Conditions
Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva, Lichen Planus of Vulva, Lichen Simplex of Vulva (Disorder)
Interventions
7-0940
Device
Lead sponsor
Stratpharma AG
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Birmingham, Alabama • Burbank, California • Laguna Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 3 Interventional

The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse

NCT00803335
View directory record Official record
Conditions
Pelvic Organ Prolapse, Vaginal Atrophy
Interventions
Vaginal conjugated estrogen cream 0.5gm, Vaginal conjugated estrogen cream 1.0gm
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
45 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 28, 2026, 1:04 PM EDT
Recruiting Phase 2 Interventional

Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women

NCT06197568
View directory record Official record
Conditions
Vulvo Vaginal Atrophy (VVA)
Interventions
Lasofoxifene Tartrate
Drug
Lead sponsor
Azure Biotech Inc.
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy

NCT01358760
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
32
States / cities
Montgomery, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial

NCT04079218
View directory record Official record
Conditions
HIV Infection, Vaginal Atrophy, Menopause, Menopause Related Conditions, Aging, Premature Aging, Atrophic Vaginitis, Dysbiosis, Vaginitis
Interventions
Estradiol Vaginal Insert
Drug
Lead sponsor
Kerry Murphy
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Twelve Week Study to Investigate the Efficacy of Femarelle®, for the Treatment of Post Menopausal Vaginal Atrophy

NCT01502527
View directory record Official record
Conditions
Vulvo Vaginal Atrophy
Interventions
Femarelle
Dietary Supplement
Lead sponsor
Dr. Lila Nachtigall Rapid Medical Research, New York
Other
Eligibility
40 Years to 85 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia

NCT01845649
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream, Vehicle
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 28, 2026, 1:04 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment Outcomes

NCT03547089
View directory record Official record
Conditions
Vaginal Atrophy, Genitourinary System; Disorder, Female, Vaginal Abnormality, Sexual Dysfunction, Sexual Problem
Interventions
Viveve®
Device
Lead sponsor
W. Grant Stevens, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Marina del Rey, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Results available

Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA

NCT02784613
View directory record Official record
Conditions
Vulvovaginal Atrophy, Dyspareunia
Interventions
Ospemifene
Drug
Lead sponsor
Sue Goldstein
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women

NCT01400776
View directory record Official record
Conditions
Postmenopausal Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream, Vehicle
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
70
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Topical DHEA Against Vaginal Atrophy

NCT01846442
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA (0.25%), DHEA (0.5%), DHEA (1.0%)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Cleveland, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 3 Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

NCT00196378
View directory record Official record
Conditions
Menopause
Interventions
Synthetic Conjugated estrogens, B, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
38
States / cities
Huntsville, Alabama • Tucson, Arizona • Carmichael, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2013 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

NCT02449902
View directory record Official record
Conditions
Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions
Estradiol, placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Vaginal and Urinary Microbiome Trial

NCT02869165
View directory record Official record
Conditions
Atrophic Vaginitis, Menopause, Recurrent Urinary Tract Infections
Interventions
Conjugated equine estrogen topical cream, Apricot kernel oil
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Sep 28, 2026, 1:04 PM EDT
Completed Not applicable Interventional

An Innovative Silicone Wound Dressing for the Management of Atrophic Vaginitis

NCT05432154
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Film forming silicone gel (7-0940)
Device
Lead sponsor
Stratpharma AG
Industry
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Sep 28, 2026, 1:04 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors

NCT03257670
View directory record Official record
Conditions
Dyspareunia
Interventions
4% Topical Lidocaine Gel, CO2RE fractional laser therapy
Drug · Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 28, 2026, 1:04 PM EDT